Flubrotizolam presents itself as a novel benzodiazepine analogue. Developed for clinical purposes, flubrotizolam possesses intense anxiolytic effects. Its structural properties illustrate a high affinity for the GABA receptor, resulting significant CNS depression. Although its potential therapeutic applications, flubrotizolam's unregulated use has